Newer biomarkers in acute coronarysyndrome

1. Novel Myocardial Injury / Necrosis Biomarkers

High-Sensitivity Cardiac Troponin (hs-cTnI / hs-cTnT)

Although now standard, they represent a newer generation.

  • Detects injury within 1–2 hours
  • Enables 0/1-hour and 0/2-hour rule-out algorithms
  • Prognostic even at low-level elevations
  • Limitation: non-ischemic elevations (CKD, sepsis, myocarditis)

Heart-Type Fatty Acid–Binding Protein (H-FABP)

  • Cytosolic protein released earlier than troponin (1–3 hours)
  • Useful in very early presenters
  • Limited specificity
  • Adjunctive, not standalone

2. Biomarkers of Myocardial Stress and Hemodynamic Load

Copeptin

(C-terminal portion of pro-vasopressin)

  • Rises immediately after symptom onset
  • Useful with negative initial troponin
  • High negative predictive value for early rule-out
  • Less useful once hs-troponins are available

BNP / NT-proBNP

  • Reflects ventricular wall stress
  • Strong prognostic marker in ACS
  • Predicts:
    • Heart failure
    • Mortality
    • Cardiogenic shock
  • Not diagnostic of MI per se

3. Biomarkers of Inflammation and Plaque Instability

High-Sensitivity C-Reactive Protein (hs-CRP)

  • Marker of vascular inflammation
  • Predicts:
    • Recurrent MI
    • Mortality
  • Independent of troponin
  • Basis for anti-inflammatory strategies (e.g., COLCOT, CANTOS)

Interleukin-6 (IL-6)

  • Central inflammatory cytokine
  • Correlates with:
    • Plaque instability
    • Infarct size
  • Prognostic rather than diagnostic

Myeloperoxidase (MPO)

  • Released from activated neutrophils
  • Reflects plaque vulnerability
  • Elevated even before troponin rise
  • Associated with recurrent ischemic events

4. Biomarkers of Plaque Rupture and Thrombosis

Pregnancy-Associated Plasma Protein-A (PAPP-A)

  • Metalloproteinase involved in plaque rupture
  • Elevated in unstable plaques
  • Less reliable with statin or heparin therapy

Soluble CD40 Ligand (sCD40L)

  • Marker of platelet activation
  • Associated with thrombotic risk
  • Limited clinical adoption

D-Dimer

  • Reflects active thrombosis and fibrinolysis
  • Prognostic in ACS
  • High levels predict mortality and adverse outcomes

5. Biomarkers of Ischemia (Before Necrosis)

Ischemia-Modified Albumin (IMA)

  • Altered albumin during ischemia
  • Rises before necrosis
  • Low specificity
  • Rarely used now

6. Emerging and Experimental Biomarkers

MicroRNAs (miRNAs)

  • Cardiac-specific (miR-1, miR-133, miR-208, miR-499)
  • Rise early after myocardial injury
  • Potential future role in:
    • Early diagnosis
    • Infarct phenotyping
  • Currently research-level

Growth Differentiation Factor-15 (GDF-15)

  • Stress-responsive cytokine
  • Strong prognostic marker
  • Incorporated into bleeding and mortality risk models

ST2 (Soluble Suppression of Tumorigenicity-2)

  • Marker of myocardial fibrosis and stress
  • Prognostic in ACS with heart failure

7. Practical Clinical Perspective (Exam + Real World)

PurposeBest Biomarkers
Early rule-ouths-Troponin ± Copeptin
Risk stratificationhs-Troponin, NT-proBNP, GDF-15
Inflammationhs-CRP, IL-6
Plaque instabilityMPO, PAPP-A
PrognosisNT-proBNP, hs-CRP, GDF-15

Key Take-Home Points

  • hs-Troponin remains the cornerstone of ACS diagnosis
  • Newer biomarkers are mainly adjunctive and prognostic
  • Inflammation-related biomarkers are gaining importance due to therapeutic implications
  • Most novel markers are not yet guideline-mandated for routine care
1. Which biomarker rises immediately after symptom onset and improves early ACS rule-out when combined with hs-troponin?
A. H-FABP
B. Copeptin
C. MPO
D. IMA
Copeptin reflects acute endogenous stress and rises before myocardial necrosis markers.
2. The major diagnostic limitation of high-sensitivity troponin assays is:
A. Poor sensitivity
B. Delayed elevation
C. Lack of ischemic specificity
D. Poor prognostic value
hs-Troponin detects myocardial injury, not ischemia alone.
3. Which biomarker best reflects plaque vulnerability rather than myocyte necrosis?
A. hs-cTnT
B. NT-proBNP
C. Myeloperoxidase
D. CK-MB
MPO is released from activated neutrophils and indicates unstable plaque biology.
4. Which ACS biomarker is significantly affected by heparin administration?
A. hs-CRP
B. PAPP-A
C. GDF-15
D. Copeptin
PAPP-A is heparin-sensitive, limiting its routine clinical use.
5. Which biomarker most strongly predicts short-term mortality in ACS independent of troponin?
A. IMA
B. NT-proBNP
C. H-FABP
D. CK-MB
NT-proBNP reflects ventricular wall stress and prognosis.
6. Biomarker that provided biological rationale for anti-inflammatory therapy in post-MI trials:
A. hs-CRP
B. D-dimer
C. Copeptin
D. ST2
hs-CRP underpinned CANTOS and COLCOT.
7. A biomarker elevated even before troponin rise and linked to recurrent ischemic events:
A. NT-proBNP
B. IL-6
C. MPO
D. ST2
MPO rises early and predicts future coronary events.
8. Marker reflecting platelet activation and thrombotic risk in ACS:
A. IL-6
B. sCD40L
C. hs-CRP
D. Copeptin
sCD40L reflects platelet-driven inflammation and thrombosis.
9. Which biomarker is mainly prognostic and incorporated into bleeding/mortality risk models?
A. IMA
B. MPO
C. GDF-15
D. H-FABP
GDF-15 is a stress cytokine strongly linked to adverse outcomes.
10. Biomarker that reflects ischemia before necrosis but has poor specificity:
A. Ischemia-modified albumin
B. hs-cTnI
C. NT-proBNP
D. CK-MB
IMA rises early but lacks specificity and is rarely used now.
11. A patient with NSTEMI has modest troponin rise but very high hs-CRP. This discordance best suggests:
A. Analytical troponin error
B. Reinfarction
C. High inflammatory plaque burden
D. Type 2 MI
hs-CRP reflects vascular inflammation and plaque activity, not infarct size. NEET-SS trap: Prognosis may be poor despite small troponin rise.
12. Which biomarker improves early rule-out of MI specifically in very early presenters (<1 hour)?
A. GDF-15
B. Copeptin
C. NT-proBNP
D. IL-6
Copeptin rises immediately with endogenous stress. Exam pearl: Value decreases once hs-troponin algorithms mature.
13. Which biomarker correlates best with recurrent ischemic events despite optimal DAPT?
A. hs-CRP
B. NT-proBNP
C. MPO
D. CK-MB
MPO reflects plaque vulnerability independent of thrombosis. Trap: High MPO ≠ larger infarct.
14. Which biomarker is least useful once hs-troponin assays are universally available?
A. NT-proBNP
B. Copeptin
C. hs-CRP
D. GDF-15
hs-Troponin largely replaces copeptin for early diagnosis. Still prognostic: Copeptin ≠ useless.
15. Which marker predicts heart failure and cardiogenic shock after ACS?
A. MPO
B. NT-proBNP
C. IMA
D. PAPP-A
NT-proBNP reflects LV wall stress and remodeling. NEET-SS pearl: Stronger predictor than EF alone.
16. A biomarker integrated into bleeding-risk and mortality models in ACS:
A. hs-CRP
B. MPO
C. GDF-15
D. Copeptin
GDF-15 reflects cellular stress and frailty. Exam trap: Not a diagnostic MI marker.
17. Which biomarker rises early but lacks specificity due to elevation in PE, sepsis, and stroke?
A. Ischemia-modified albumin
B. hs-Troponin
C. NT-proBNP
D. MPO
IMA detects ischemia, not coronary ischemia specifically. Hence: Largely abandoned clinically.
18. Which biomarker reflects platelet-mediated inflammation and thrombosis?
A. IL-6
B. sCD40L
C. hs-CRP
D. NT-proBNP
sCD40L is released from activated platelets. Exam link: Thrombo-inflammatory axis.
19. Which biomarker most closely correlates with infarct size on CMR?
A. hs-CRP
B. hs-Troponin
C. MPO
D. GDF-15
Troponin correlates with necrotic mass. Trap: hs-CRP correlates with risk, not size.
20. Elevated D-dimer in ACS primarily indicates:
A. Larger infarct
B. Plaque rupture
C. Active thrombosis and fibrinolysis
D. LV remodeling
D-dimer is prognostic, not diagnostic. Exam trap: High mortality predictor.
21. In a patient with CKD stage 4 and chest pain, which biomarker retains the highest prognostic value?
A. hs-Troponin
B. CK-MB
C. NT-proBNP
D. IMA
Troponin is often chronically elevated in CKD. NT-proBNP remains strongly prognostic. NEET-SS trap: Diagnostic vs prognostic distinction.
22. Which biomarker best differentiates Type 1 MI from Type 2 MI?
A. hs-Troponin magnitude
B. MPO elevation
C. NT-proBNP
D. D-dimer
MPO reflects plaque rupture biology typical of Type-1 MI. Trap: Troponin height alone cannot differentiate MI type.
23. A biomarker that predicts benefit from colchicine therapy post-ACS:
A. hs-CRP
B. NT-proBNP
C. GDF-15
D. MPO
Anti-inflammatory benefit is greatest when hs-CRP is elevated. Exam link: COLCOT, CANTOS paradigm.
24. Which biomarker reflects myocardial fibrosis and adverse remodeling?
A. MPO
B. ST2
C. Copeptin
D. PAPP-A
ST2 signals myocardial stretch-fibrosis axis. NEET-SS pearl: Complements NT-proBNP.
25. Which biomarker is most influenced by systemic inflammatory states like sepsis?
A. hs-CRP
B. MPO
C. hs-Troponin
D. NT-proBNP
hs-CRP is non-specific inflammation marker. Trap: Does not localize pathology to coronaries.
26. Which biomarker shows promise for ultra-early diagnosis but remains research-level?
A. IMA
B. MPO
C. Cardiac microRNAs
D. sCD40L
miR-1, miR-133, miR-208 rise early but lack standardization.
27. Which biomarker elevation best predicts bleeding risk with aggressive antithrombotic therapy?
A. hs-CRP
B. NT-proBNP
C. GDF-15
D. MPO
GDF-15 integrates frailty, renal dysfunction, and bleeding risk.
28. A biomarker that may be elevated even before ECG changes:
A. CK-MB
B. Copeptin
C. NT-proBNP
D. hs-CRP
Stress hormone activation precedes electrical and necrotic changes.
29. Elevated hs-CRP with normal troponin most strongly predicts:
A. Large MI
B. False positive result
C. Future cardiovascular events
D. Heart failure
Inflammatory risk ≠ infarct size. Exam trap: Long-term prognosis question.
30. Which biomarker is most useful for population-level risk stratification rather than bedside diagnosis?
A. hs-Troponin
B. hs-CRP
C. CK-MB
D. Copeptin
hs-CRP widely used in preventive cardiology.
31. Which biomarker is most affected by statin therapy?
A. hs-CRP
B. hs-Troponin
C. NT-proBNP
D. D-dimer
Statins reduce inflammation independent of LDL.
32. Which biomarker reflects both thrombotic burden and systemic hypercoagulability?
A. MPO
B. PAPP-A
C. D-dimer
D. hs-CRP
D-dimer integrates thrombosis + fibrinolysis.
33. Which biomarker is LEAST useful for diagnosing reinfarction?
A. CK-MB
B. Serial hs-Troponin delta
C. Clinical context
D. hs-CRP
Inflammation persists long after infarction.
34. Which biomarker best predicts sudden cardiac death post-MI?
A. hs-CRP
B. NT-proBNP
C. MPO
D. IMA
Reflects LV dysfunction and arrhythmic substrate.
35. A biomarker elevated in ACS but also predicts non-cardiovascular mortality:
A. hs-Troponin
B. MPO
C. GDF-15
D. CK-MB
Reflects global cellular stress and frailty.
36. Which biomarker best explains persistent risk despite optimal LDL lowering?
A. hs-Troponin
B. hs-CRP
C. NT-proBNP
D. CK-MB
Residual inflammatory risk persists despite lipid control. Exam pearl: hs-CRP identifies candidates for anti-inflammatory therapy.
37. A biomarker elevated in ACS but unaffected by reperfusion success:
A. hs-Troponin
B. CK-MB
C. hs-CRP
D. Copeptin
Inflammation continues despite vessel patency. Trap: Reperfusion lowers necrosis markers, not inflammatory ones.
38. Which biomarker combination best captures ischemia + necrosis + prognosis?
A. CK-MB + D-dimer
B. hs-Troponin + NT-proBNP
C. hs-CRP + MPO
D. Copeptin + IMA
Troponin = necrosis; NT-proBNP = hemodynamic stress. NEET-SS insight: Dual-marker strategy improves risk stratification.
39. Which biomarker is most useful for identifying patients who benefit from early invasive strategy?
A. hs-Troponin
B. hs-CRP
C. D-dimer
D. IMA
Troponin-positive NSTE-ACS derives maximal benefit from invasive strategy.
40. A biomarker elevated in ACS, sepsis, malignancy, and aging — limiting specificity:
A. MPO
B. NT-proBNP
C. GDF-15
D. hs-Troponin
GDF-15 reflects generalized cellular stress. Trap: Powerful prognostic but poor diagnostic marker.
41. Which biomarker best reflects the concept of “vulnerable patient” rather than “vulnerable plaque”?
A. MPO
B. PAPP-A
C. NT-proBNP
D. sCD40L
NT-proBNP integrates myocardial, renal, and systemic risk.
42. Which biomarker is most useful for identifying patients at risk of post-MI heart failure?
A. hs-CRP
B. NT-proBNP
C. MPO
D. IMA
NT-proBNP outperforms EF in early risk prediction.
43. Which biomarker is most influenced by circadian variation and stress response?
A. Copeptin
B. hs-Troponin
C. NT-proBNP
D. hs-CRP
Copeptin mirrors vasopressin stress-axis activation.
44. Which biomarker is LEAST affected by renal dysfunction?
A. NT-proBNP
B. hs-Troponin
C. GDF-15
D. hs-CRP
Inflammatory markers are least influenced by GFR.
45. Which biomarker most strongly correlates with long-term all-cause mortality?
A. hs-Troponin
B. MPO
C. GDF-15
D. CK-MB
GDF-15 integrates cardiovascular and non-cardiovascular risk.
46. Which biomarker is most useful for differentiating myocardial injury from myocardial infarction?
A. hs-Troponin absolute value
B. CK-MB
C. Clinical context + troponin delta
D. hs-CRP
Diagnosis of MI is biochemical + clinical, not biomarker alone.
47. Which biomarker is most useful in predicting arrhythmic risk post-MI?
A. hs-CRP
B. NT-proBNP
C. MPO
D. D-dimer
Reflects ventricular stretch and electrical instability substrate.
48. Which biomarker best reflects thrombo-inflammatory interaction?
A. hs-CRP
B. NT-proBNP
C. sCD40L
D. IMA
sCD40L bridges platelet activation and inflammation.
49. Which biomarker is most helpful in deciding intensity of secondary prevention?
A. CK-MB
B. hs-CRP
C. IMA
D. Copeptin
Persistent inflammation = need for aggressive risk modification.
50. The single most important limitation preventing routine use of most newer ACS biomarkers is:
A. Poor sensitivity
B. Poor reproducibility
C. Lack of guideline-mandated clinical impact
D. Cost alone
Most markers are prognostic without altering management decisions.
newer biomarkers in acute coronary syndrome
newer biomarkers in acute coronary
syndrome
    Subscribe Medicine Question BankWhatsApp Channel
    Click Here - WhatsApp Channel

    FREE Updates, MCQs & Questions For Doctors & Medical Students

    No thanks, I’m not interested!

      Medicine Question Bank
      Click & Follow WhatsApp Channel